TY - JOUR

T1 - Affective and non-affective cognition in patients with bipolar disorder type I and type II in full or partial remission

T2 - Associations with familial risk

AU - Jensen, Mette Bagge

AU - Kjærstad, Hanne Lie

AU - Coello, Klara

AU - Stanislaus, Sharleny

AU - Melbye, Sigurd

AU - Sletved, Kimie Ormstrup

AU - Vinberg, Maj

AU - Kessing, Lars Vedel

AU - Miskowiak, Kamilla Woznica

PY - 2021

Y1 - 2021

N2 - Background: The upcoming conversion of the ICD-11 will subdivide patients with bipolar disorder (BD) into BD type I (BD-I) and BD type II (BD-II). This study aimed to investigate whether cognitive impairments could aid as objective cognitive biomarkers for recently diagnosed BD subtypes by comparing cognitive profiles between BD subtypes, their unaffected relatives (UR), and healthy controls (HC). Methods: The sample included 76 patients with BD-I, 149 patients with BD-II, 28 UR of patients with BD-I (UR-I), 50 UR of patients with BD-II (UR-II) and 168 HC from the Bipolar Illness Onset study, who were assessed with an extensive non-affective and affective cognitive test battery. Results: The results showed no significant differences in affective or non-affective cognition between BD-I and BD-II. Compared to HC, patients with BD-I (but not BD-II) showed worse performance in verbal fluency (p =.01) and were slower at recognising fearful faces (p =.045), while patients with BD-II (but not BD-I) displayed generally poorer recognition of facial expressions (p =.02). Only UR-I showed lower performance on verbal fluency (p =.049) and aberrant affective cognition (ps≤.047) compared to HC. Limitations: The potential confounding effects of medication were not explored. Conclusions: The lack of significant differences in cognitive profiles between recently diagnosed BD-I and BD-II suggests that neither affective nor non-affective cognition are indicative of BD subtype.

AB - Background: The upcoming conversion of the ICD-11 will subdivide patients with bipolar disorder (BD) into BD type I (BD-I) and BD type II (BD-II). This study aimed to investigate whether cognitive impairments could aid as objective cognitive biomarkers for recently diagnosed BD subtypes by comparing cognitive profiles between BD subtypes, their unaffected relatives (UR), and healthy controls (HC). Methods: The sample included 76 patients with BD-I, 149 patients with BD-II, 28 UR of patients with BD-I (UR-I), 50 UR of patients with BD-II (UR-II) and 168 HC from the Bipolar Illness Onset study, who were assessed with an extensive non-affective and affective cognitive test battery. Results: The results showed no significant differences in affective or non-affective cognition between BD-I and BD-II. Compared to HC, patients with BD-I (but not BD-II) showed worse performance in verbal fluency (p =.01) and were slower at recognising fearful faces (p =.045), while patients with BD-II (but not BD-I) displayed generally poorer recognition of facial expressions (p =.02). Only UR-I showed lower performance on verbal fluency (p =.049) and aberrant affective cognition (ps≤.047) compared to HC. Limitations: The potential confounding effects of medication were not explored. Conclusions: The lack of significant differences in cognitive profiles between recently diagnosed BD-I and BD-II suggests that neither affective nor non-affective cognition are indicative of BD subtype.

KW - Biomarker

KW - Bipolar disorder

KW - Cognition

KW - Relatives

KW - Risk

KW - Subtypes

U2 - 10.1016/j.jad.2021.01.074

DO - 10.1016/j.jad.2021.01.074

M3 - Journal article

C2 - 33561801

AN - SCOPUS:85100433186

VL - 283

SP - 207

EP - 215

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -